In the Lancet Respiratory Medicine, the results of the assessment of early administration of simvastatin for the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS) trial¹ indicated that simvastatin did not increase the number of days that these patients spent without coma or delirium. To assess the cost-effectiveness of treatments however, the National Institute of Health and Care Excellence (NICE)² recommend quantifying the effect of the intervention on health-related quality of life using quality-adjusted life-years (QALYs).

中文翻译：

---

辛伐他汀用于预防和治疗重症机械通气患者（MoDUS）的ir妄：成本效益分析

在《柳叶刀呼吸医学》中，在机械通气（MoDUS）试验^1的危重患者中，早期给予辛伐他汀用于预防和治疗del妄的评估结果表明，辛伐他汀不会增加这些患者在不进行机械通气的情况下所花费的天数昏迷或del妄。为了评估治疗的成本效益，美国国立卫生与医疗保健研究院（NICE）²建议使用质量调整生命年（QALYs）量化干预措施对与健康相关的生活质量的影响。